Background
Methods
In this study, we enrolled 25 newly diagnosed HSPN patients and 14 healthy controls. Then, fractions of B cell subtypes were determined in venous blood using flow cytometry. The serum interleukin (IL)-10 concentration was determined by enzyme-linked immunosorbent assay.
Results
Compared to those in healthy controls, the numbers of CD38 
Introduction
Henoch-Schoenlein purpura (HSP) is a systemic vasculitis that affects small vessels. In this condition, patients develop perivascular inflammatory cell infiltrates. It is an immunoglobulin A-related immune complex-mediated disease that adversely affects the skin, joints, and gastrointestinal system, especially the kidney [1, 2] . In recent studies, it has been reported that glomerular damage occurs in patients with HSPN, and such damage might be due to the deposition of mesangial Gd-IgA1-containing immune complex, which acts as a potential mediator via mesangial receptors. Subsequently, complement-mediated stimulation of mesangial cells occurs, leading to their proliferation. Moreover, cytokine secretion is also stimulated under such circumstances [3] . However, IgA deposition recurs in some patients even after they undergo renal transplantation [4, 5] . In such patients, we detect mild forms of IgA nephropathy (IgAN), because there is deposition of immune complex and nephritic changes [6] . As a result, we usually detect an extrarenal source of antigen and an antibody immune complex in these patients. Furthermore, B cells are divided into different subsets depending on the presence of surface molecules. In the peripheral blood, naive and memory B cells express different amounts of CD27 [7] . This indicates that activated CD27 + B cells can establish memory responses [8] .
Activated B cells can differentiate into CD38 + plasma cells that secrete antibodies [9, 10] and cytokines, which enhance the expression of co-stimulation molecules, especially CD86 (which is an established marker of B-cell activation) and CD95 [11, 12] . The CD95 receptor is considered to be a key regulator in the activation of germ cell apoptosis [13] . These different subtypes of B cells are known to collaborate and control the responses of the human immune system; however, very little information is available regarding the mechanisms governing the onset of HSPN in patients. B cells are primary positive regulators that have the ability to produce Ag-specific Ig and multiple cytokines. However, regulatory B cells (Bregs), which are a subset of B cells, have been found to have negative regulatory function [14] . Presently, in murine models with autoimmune disease, scientists have established that Breg subsets have immunosuppressive activity. This includes B cell subsets that express interleukin (IL)-10 and transforming growth factor (TGF)-β, which can facilitate the recruitment and expansion of regulatory T cells (Tregs) [15] [16] [17] [18] [19] [20] [21] [22] . In preliminary studies, scientists have proved that Bregs play a critical regulatory role in experimental autoimmune encephalomyelitis (EAE). Moreover, they also suppress intestinal inflammation in murine models [23, 24] . In previous studies, we have proved that activated B and T follicular helper (TFH) cells can contribute to the pathogenesis of minimal change disease (MCD) and hepatitis B virus-associated membranous nephropathy (HBV-MN) [25, 26] . In addition, we have found that several CD19 + B cell subtypes and IL-10 + Bregs are differentially expressed in IgA-nephritis patients [27] . Moreover, previous studies have also reported that IL-10-producing B cells are actively involved in regulating Th1 and Th17 responses in a model of collagen-induced arthritis [28] . In these models, B cells that produce IL-10 play a critical  role, and a new IL-10  + B cell subset was recently characterized by a CD1d  hi CD5  + CD19  + pheno- type [14, [29] [30] [31] . Presently, very little information is available about the association between Bregs and HSPN.
In this study, we evaluated the numbers (per microliter of blood) of various B cell subtypes and IL-10-producing B cells that were isolated from the peripheral blood of patients with HSPN and healthy controls (HCs). Thus, we investigated the potential association between the differential expression of B cell subtypes before treatment and the dynamic changes in these B cell subtypes after treatment.
Materials and Methods

Patients and controls
A total of 25 patients with new onset HSPN (defined by a disease duration of <2 months) were recruited through the inpatient service of the Department of Nephrology of the First Hospital of Jilin University from January 2015 to October 2015. We excluded patients with any of the following conditions: IgA-nephritis, lupus nephritis, other primary glomerulonephritides, neoplastic disease, active peptic ulcer, diabetes mellitus, and viral hepatitis. In the control group, we included 14 HCs who matched the experimental subjects in terms of age, gender and ethnicity. None of the subjects in the control group had a history of any kind of chronic inflammatory disease. All the included patients fulfilled the EULAR/PRINTO/PRES (European League against Rheumatism/Paediatric Rheumatology International Trials Organisation/Paediatric Rheumatology European Society) criteria for HSP, which is defined as purpura plus; the included patients experienced at least one of the following symptoms: 1) abdominal pain; 2) typical leukocytoclastic vasculitis or proliferative glomerulonephritis with IgA deposits, as confirmed by histopathological examination; 3) arthritis or arthralgia; and 4) renal involvement [32] . HSPN patients develop either a nephritic or a nephrotic syndrome. Nephritic syndrome is defined as hematuria with at least one of the following symptoms: renal insufficiency, hypertension, and oliguria. Here, nephrotic syndrome was defined by proteinuria >400 mg/day or hematuria. In some studies, it has been reported that patients with nephrotic syndrome also develop edema and have serum albumin levels <2.5 g/dl [33, 34] . All the participants signed a written informed consent form, and this study was approved by the Ethical Committee of the First Hospital of Jilin University. The demographic and clinical characteristics of participants are summarized in Table 1 .
Treatment and follow-up
Individual patients were treated orally with glucocorticoid prednisolone (PDN, Tianyao Pharmaceuticals, Tianjin China) in a 1 mg/kg/day dosage for the first 2 months. This dosage of steroids was gradually tapered, and a maintenance dose of 10 mg/day was prescribed to these patients for the next 6 months, or a combination of oral immunosuppressants (tacrolimus capsules, 1 mg/day) to relieve urinary proteinuria. In addition, some patients were at a higher risk of developing a hypercoagulable state, and they were treated with dipyridamole (25 mg/day, Yunpeng Pharmaceutical, Shanxi, China). The patients were followed up for 8-12 weeks. Eight patients had complete records, and the other 17 patients were censored on follow-up. Blood samples for measurement of clinical lab values, B-cell values and IL-10 concentrations were collected before and after the treatment from January 2015 to June 2015.
Clinical examination
Venous blood samples (10 ml) were obtained from each participant; the blood samples were collected in heparinized tubes. A small volume of blood was used for isolating peripheral blood mononuclear cells (PBMCs) using density-gradient centrifugation (Amersham Biosciences, Little Chalfont, UK). The remaining blood samples were centrifuged for preparing serum samples. We determined the concentrations of serum triglycerides, serum IgA cholesterol, albumin, uric acid, leukocytes and lymphocytes using ADVIA 1650 biochemical analyzer (Bayer, Pittsburg, PA, USA). Moreover, we collected 24-hour urine samples from individual subjects to examine urinary proteinuria and microscopic hematuria. In addition, we calculated the estimated glomerular fitration rate (eGFR) of individual participants using the revised eGFR formula [35] .
Flow cytometric analysis
Human PBMCs were stained at a cell density of 10 6 /tube in duplicates. For the purpose of staining, we used PerCP-anti-CD19, PE-anti-CD38, APC-anti-CD86, or PerCP-anti-CD19, PE-anti-CD27, and APC-anti-CD95 or isotype-matched control IgG (BD Biosciences, San Jose, CA, USA). The staining was performed at room temperature, and the cells were protected from light for 30 minutes. After washing with phosphate-buffered saline (PBS), the cells were characterized using a FACS Calibur flow cytometer (BD Biosciences). Moreover, at least 30000 events per sample were analyzed using FlowJo software v7.6.2 (Ashland, OR, USA) [36] .
To analyze the production of intracellular IL-10, we isolated PBMCs. The cells were then plated in 24-well plates (10 6 cells/well) and stimulated with 50 ng/ml phorbol myristate acetate (PMA), 1.0 mg/ml ionomycin and 5.0 mg/ml lipopolysaccharide (LPS; Sigma-Aldrich, St. Louis, MO, USA) in complete RPMI-1640 medium for 2 h at 37°C in an atmosphere of 5% CO 2 . Then, brefeldin A (GolgiPlug; BD Biosciences) was added to each well, and the cells were incubated for another 4 h. Then, the cells were harvested and washed with PBS. Finally, these cells were stained in duplicate for 30 min using APC-anti-CD19, PE-anti-CD1d, and PerCPanti-CD5 (BD Biosciences). After washing with PBS, the cells were permeabilized using a permeabilization solution (BD Biosciences). Thereafter, they were stained using FITC-anti-IL-10 (eBiosciences, San Diego, CA, USA). Finally, they were analyzed by flow cytometry using the aforementioned procedure. The details of the antibodies used for flow cytometry are provided in S1 Table. Enzyme-linked immunosorbent assay (ELISA)
The serum concentration of IL-10 was determined by ELISA using a human IL-10 ELISA kit (Roche Diagnostics, Lewes, UK) according to the manufacturer's instructions. At 1:4 dilutions, individual serums were briefly subjected to ELISA analysis. Thereafter, the serum concentrations of IL-10 were calculated in individual samples using the standard curve established for recombinant IL-10. The detection limit was 2.5 ng/L.
Human cell isolation and culture
We isolated B cells from PBMCs of five new onset HSPN patients via flow cytometry and staining with APC-anti-CD19 (BD Biosciences). The B cells were resuspended in D-10 (DMEM supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin). Experiments were carried out in duplicate, and cell numbers were equal among the two groups for each patient: one group of D-10 with 1 μM prednisolone, and the other group without prednisolone. These samples were then distributed in wells of 24-well plates (Corning, Tewksbury, MA, USA) at 0.5-2×10 5 cells per well. After incubation at 37°C in a humidified atmosphere with 5% CO 2 for 72 h, all cells in culture wells were harvested and stained with PE-anti-CD1d and PerCP-anti-CD5 (BD Biosciences) as described to determine the percentages of Bregs.
Statistical analysis
Data are expressed as means, medians, and ranges. The numbers of each type of cells tested were calculated according to the percentages of each type of cells multiplied by the lymphocyte count. The differences between the two groups were analyzed using Mann-Whitney U-test. The differences between pre-treatment and post-treatment patients were analyzed by the Wilcoxon test. The correlations were tested using Spearman's rank correlation test. Statistical analysis was performed using SPSS 19.0 software (IBM, Armonk, NY, USA). Statistically significant cases were those in which the two-sided P-value <0.5.
Results
Patient characteristics
There were no significant differences in the ages and gender ratio of HSPN patients and HCs. There were also no significant differences in the serum albumin concentration, serum uric acid concentration, urea nitrogen concentration, triglycerides, cholesterol, and lymphocyte counts of experimental cases and HCs. However, HSPN patients had significantly higher values of 24-h proteinuria compared to the control group. In addition, HSPN patients had a significantly lower eGFR compared to the HCs (Table 1) . The clinical and basic immunological parameters of all individual patients and controls are described in S2 Table. Differential expression of B cell subsets Fig 2B-2E) . Because Bregs play an immunoregulatory role that is primarily mediated via IL-10, we examined the serum concentrations of IL-10 in HSPN patients and HCs. We found that the serum IL-10 concentration was significantly lower in the HSPN patients (P<0.001, Fig 2F) . Our raw data can be found in S1 Clinical parameters, different subsets of B cells, and serum IL-10 concentration in HSPN patients following treatment
In order to better understand the function of different subsets of B cells and serum IL-10 in the progression of HSPN, we assessed the values of clinical parameters, the numbers of B cells of different subsets, and the serum IL-10 concentrations in eight patients who reported for follow-up sessions within 8-12 weeks. We found that 24-h proteinuria had decreased significantly in these patients, whereas eGFR had increased (Table 2 ). In addition, the serum level of IL-10 had significantly increased as compared to the pre-treatment levels (Fig 5A, P = 0.002) . Similarly, the numbers of IL-10 + CD19 + (Fig 5D, P<0 .001), CD1d + CD5 + CD19 + (Fig 5E, P<0. 
Discussion
Previous studies have failed to clarify the pathogenesis of HSPN. However, they have proved that HSPN is mainly associated with glomerular deposits of an immune complex containing IgA. These deposits are primarily found in mesangium. Moreover, the deposition of IgA occurs again in some patients who have previously undergone renal transplantation [3] . In our study, we have characterized the roles of different subsets of peripheral blood B cells in HSPN patients and HCs. In our study, the different B cell subsets were defined as CD38 + CD19 + , [12] . Activated B cells can also secrete cytokines and express co-stimulatory molecules, such as CD86 and CD95 [11] . Furthermore, it has been proposed that CD95 acts as a key regulator in the activation of germ cell apoptosis [13] . Previous studies have also shown that Bregs play a critical role in the regulation of experimental autoimmune encephalomyelitis (EAE) and in the suppression of intestinal inflammation in murine models via IL-10, which has strong anti-inflammatory activity and inhibitory activity on the immune system [23, 24] . Therefore, we analyzed the correlations between CD19 + B cell subtypes and the IL-10-producing B cells. We have found that the number of can predict the pathological classification of HSPN [37] . Given that HSPN is a serious pathological condition arising from Henoch-Schoenlein purpura, we analyzed the numbers of neutrophils from the patients with HSPN to explore whether our findings represent only a general inflammatory response. We found that the number of Bregs has no correlation with the number of neutrophils (data not shown), suggesting that our findings do not represent a general inflammatory response. Although previous studies have shown that the levels of CD5 + B cells and IL-10 + B cells are decreased in antineutrophil cytoplasmic antibody-associated vasculitis [38] [39] [40] [41] and the frequency of IL-10-producing B cells is higher in hepatitis B virus-associated membranous nephropathy [42] [44, 45] . Thus, further dissection of the actual association with either of these subsets is needed. Nonetheless, our data provide novel insights into the unknown pathophysiology and mechanisms of HSPN. Further studies should be conducted to explore the roles of different subsets of B cells in the pathogenesis of HSPN and to gain an understanding of the mechanisms of regulation and activation of Bregs. Such studies are likely to identify a new target that can be used for medical intervention in HSPN patients.
